Cardiac manifestations of idiopathic hypereosinophilic syndrome |
| |
Authors: | Harzy T Allali F Amine B Rahmouni R Hajjaj-Hassouni N |
| |
Affiliation: | Service de rhumatologie B , h?pital El-Ayachi, CHU de Rabat-Salé, Maroc. t.harzy@caramail.com |
| |
Abstract: | BACK GROUND: The aim of our study is to describe the more common cardiac manifestations of idiopathic hypereosinophilic syndrome representing the major cause of mortality. MAIN POINTS: Current therapy consists of corticosteroid, hydroxyurea and interferon alpha. Recent publications confirm the activity of imatinib mesylate, a selective tyrosine kinase inhibitor, in patients with idiopathic hypereosinophilic syndrome. In cases with marked valvular compromise or with endomyocardial thrombosis or fibrosis, cardiac surgery can provide substantial benefits. PERSPECTIVES: A better understanding of the pathophysiology of this syndrome could lead to the development of new therapeutic agents. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|